Interaction of TP53 mutations with trastuzumab in HER2-positive patients with operable breast cancer

被引：0

作者：

Kotoula, V. ^{[1
]}

Zagouri, F. ^{[1
]}

Alexopoulou, Z. ^{[2
]}

Gogas, H. ^{[1
]}

Lakis, S. ^{[1
]}

Pentheroudakis, G. ^{[1
]}

Bobos, M. ^{[1
]}

Papadopoulou, K. ^{[1
]}

Tsolaki, E. ^{[1
]}

Skondra, M. ^{[1
]}

Karavasilis, V. ^{[1
]}

Koutras, A. ^{[1
]}

Chrisafi, S. ^{[1
]}

Christodoulou, C. ^{[1
]}

Papakostas, P. ^{[1
]}

Linardou, H. ^{[1
]}

Markopoulos, C. ^{[1
]}

Zografos, G. ^{[1
]}

Samantas, E. ^{[1
]}

Fountzilas, G. ^{[1
]}

机构：

[1] Data Off, Hellen Cooperat Oncol Grp, Athens, Greece

[2] Hlth Data Specialists Ltd, Biostat, Athens, Greece

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)30765-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1813

引用

页码：S270 / S270

页数：1

共 50 条

[21] Adjuvant trastuzumab for HER2-positive breast cancer
Spicer, J
Harries, M
Ellis, P
LANCET, 2005, 366 (9486): : 634 - 634
[22] A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations (vol 47, pg 771, 2010)
Wilson, J. R. F.
Bateman, A. C.
Hanson, H.
JOURNAL OF MEDICAL GENETICS, 2011, 48 (03) : 216 - 216
[23] Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
Darb-Esfahani, Silvia
Denkert, Carsten
Stenzinger, Albrecht
Salat, Christoph
Sinn, Bruno
Schem, Christian
Endris, Volker
Klare, Peter
Schmitt, Wolfgang
Blohmera, Jens-Uwe
Weichert', Wilko
Moebs, Markus
Teschl, Hans
Kuemmeln, Sherko
Sinn, Peter
Jackisch, Christian
Dietel, Manfred
Reimer', Toralf
Loi, Sherene
Untch, Michael
von Minckwitz, Gunter
Nekljudoval, Valentina
Loibl, Sibylle
ONCOTARGET, 2016, 7 (42) : 67686 - 67698
[24] HER2-Positive Breast Cancer: Beyond Trastuzumab
Murphy, Conleth G.
Fornier, Monica
ONCOLOGY-NEW YORK, 2010, 24 (05): : 410 - 415
[25] Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
A Langerød
TI Andersen
I Bukholm
A-L Børresen Dale
Breast Cancer Research, 2 (Suppl 1)
[26] Patients with operable HER2-positive breast cancer appear to benefit from the addition of pertuzumab to trastuzumab plus chemotherapy
Printz, Carrie
CANCER, 2020, 126 (09) : 1827 - 1827
[27] Somatic Mutations of TP53 and Prognostic Factors for Primary Operable Breast Cancer: Correspondence
Sookaromdee, Pathum
Wiwanitkit, Viroj
JOURNAL OF BREAST CANCER, 2022, 25 (06) : 522 - 522
[28] Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer - In Reply
Cianfrocca, Mary
ONCOLOGIST, 2006, 11 (05): : 534 - 534
[29] Docetaxel, carboplatin and weekly trastuzumab are active as neoadjuvant therapy in operable HER2-positive breast cancer
Kolberg, H. -C.
Akpolat-Basci, L.
Otterbach, F.
Drumm, A.
Tirier, C.
BREAST, 2011, 20 : S74 - S74
[30] Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
Li, Xuerui
Chen, Xiaoqing
Wen, Lingzhu
Wang, Yulei
Chen, Bo
Xue, Yunlian
Guo, Liping
Liao, Ning
THORACIC CANCER, 2020, 11 (07) : 1861 - 1868

← 1 2 3 4 5 →